The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study

被引:0
|
作者
Zhukova, N. [1 ]
Orlova, R. [1 ]
Malkova, A. [1 ,2 ]
Kaledina, E. [1 ]
Demchenkova, A. [1 ]
Naimushina, P. [1 ]
Nazarov, V. [3 ]
Mazing, A. [3 ]
Lapin, S. [3 ]
Belyak, N. [1 ]
Shoenfeld, Y. [1 ,2 ]
机构
[1] St Petersburg State Univ, St Petersburg, Russia
[2] Ariel Univ, Ariel, Israel
[3] Pavlov First St Petersburg State Med Univ, St Petersburg, Russia
关键词
immune checkpoint inhibitors; immune adverse events; HLA-DRB1; PD-L1; expression; diagnostic index; ADVERSE EVENTS;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune-related adverse events (irAEs) occur in up to 50% of patients treated with an anti-CTLA-4 antibody and 30% of patients treated with PD-1/PD-L1 antibodies. Severe forms of toxicity are observed in 3% of patients and require systemic steroid therapy and constant monitoring. One of the considered predictor biomarkers of irAEs development is HLA-genotypes. This research aims to evaluate the diagnostic significance of HLA-DRB1 genotypes and other clinical and laboratory parameters to predict the development of irAEs. The study involved 28 patients with metastatic melanoma taking checkpoint inhibitors therapy [nivo 53.6%, Ipi+nivo 32.1%, other (pembro, prolgo) 14.3%]. The PD-L1 expression and HLA-DRB1 genotype were evaluated. After 2-3 months the development of irAES was assessed. The complications of 3-4 grade or multi-organ damage were termed as severe irAEs. Various IrAEs developed in 57.1% (16/28) of patients, while severe irAEs occurred in 35.7% (10/28). Among all patients, HLA-DRB1 genotypes associated with the risk of autoimmune diseases were found in 78.5% (22/28). The PD-L1 expression was detected in 60.7% (17/28) of individuals. Combination treatment increases the risk of toxicity, p = 0.0028, with a diagnostic sensitivity of 56% and a diagnostic specificity of 100% (RR = 2.71, OR = 31.67). An index based on the parameters studied (HLA-DRB1, absence of PD-L1 expression, and type of treatment) was created. It allows assuming the risk of developing severe irAES (p = 0.0126). When comparing this indicator between irAEs 1-2 and irAEs 3-4, the presence of an index value of more than 2 gives a sensitivity for predicting severe toxicity of 40.00% and a specificity of 83.33%.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 25 条
  • [1] New diagnostic index for prediction of severe irAEs in patients with metastatic melanoma taking checkpoint inhibitors.
    Zhukova, Natalia V.
    Orlova, Rashida
    Malkova, Anna
    Kaledina, Ekaterina
    Demchenkova, Alexandra
    Naymushina, Polina
    Nazarov, V.
    Mazing, A.
    Lapin, S.
    Beliak, Natalia P.
    Shoenfeld, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] 18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study
    Nienhuis, Pieter H.
    Antunes, Ines F.
    Glaudemans, Andor W. J. M.
    Jalving, Mathilde
    Leung, David
    Noordzij, Walter
    Slart, Riemer H. J. A.
    de Vries, Erik F. J.
    Hospers, Geke A. P.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 899 - 905
  • [3] PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil
    Sorroche, Bruna Pereira
    Teixeira, Renan de Jesus
    Pereira, Caio Augusto Dantas
    Santana, Iara Viana Vidigal
    Vujanovic, Lazar
    Vazquez, Vinicius de Lima
    Arantes, Lidia Maria Rebolho Batista
    DIAGNOSTICS, 2023, 13 (06)
  • [4] The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell Carcinoma
    Schielke, L.
    Hadaschik, E.
    Lodde, G. C.
    Albrecht, L. J.
    Sucker, A.
    Tasdogan, A.
    Roesch, A.
    Zimmer, L.
    Livingstone, E.
    Becker, J. C.
    Schadendorf, D.
    Ugurel, S.
    Placke, J. M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 17 - 18
  • [5] Gastric inflammatory prognostic index (GIPI) to predict efficacy of PD-1/PD-L1 immune checkpoint inhibitors in metastatic gastroesophageal junction (GOJ)/gastric cancer (GC) patients.
    Morelli, Cristina
    Formica, Vincenzo
    Patrikidou, Anna
    Murias, Carmen
    Butt, Sabeeh-Ur-Rehman
    Nardecchia, Antonella
    Lucchetti, Jessica
    Renzi, Nicola
    Shiu, Kai-Keen
    Roselli, Mario
    Arkenau, Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    Feisal, James
    Balakrishna, Pragathi
    Itani, Aleena
    King, Caleb
    Acharya, Pawan
    Vesely, Sara
    Aljumaily, Raid
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
    Oyan, Basak
    Sonmez, Ozlem
    Yazar, Aziz
    Teomet, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
    Erman, Ana
    Ignjatovic, Marija
    Leskovsek, Katja
    Miceska, Simona
    Tratar, Ursa Lampreht
    Bosnjak, Masa
    Prevodnik, Veronika Kloboves
    Cemazar, Maja
    Sekulovic, Lidija Kandolf
    Avgustin, Gorazd
    Ocvirk, Janja
    Mesti, Tanja
    BIOMEDICINES, 2023, 11 (07)
  • [9] Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
    Formica, Vincenzo
    Morelli, Cristina
    Patrikidou, Anna
    Murias, Carmen
    Butt, Sabeeh
    Nardecchia, Antonella
    Lucchetti, Jessica
    Renzi, Nicola
    Shiu, Kai-Keen
    Roselli, Mario
    Arkenau, Hendrik-Tobias
    TARGETED ONCOLOGY, 2020, 15 (03) : 327 - 336
  • [10] Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
    Vincenzo Formica
    Cristina Morelli
    Anna Patrikidou
    Carmen Murias
    Sabeeh Butt
    Antonella Nardecchia
    Jessica Lucchetti
    Nicola Renzi
    Kai-Keen Shiu
    Mario Roselli
    Hendrik-Tobias Arkenau
    Targeted Oncology, 2020, 15 : 327 - 336